Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Nektar Therapeutics stock price, quote, forecast and news

NKTR
US6402681083
165417

Price

1.30
Today +/-
+0.03
Today %
+2.33 %
P

Nektar Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Nektar Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Nektar Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Nektar Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Nektar Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Nektar Therapeutics Stock Price History

DateNektar Therapeutics Price
9/20/20241.30 undefined
9/19/20241.27 undefined
9/18/20241.26 undefined
9/17/20241.30 undefined
9/16/20241.27 undefined
9/13/20241.31 undefined
9/12/20241.25 undefined
9/11/20241.25 undefined
9/10/20241.24 undefined
9/9/20241.18 undefined
9/6/20241.12 undefined
9/5/20241.13 undefined
9/4/20241.24 undefined
9/3/20241.24 undefined
8/30/20241.28 undefined
8/29/20241.27 undefined
8/28/20241.26 undefined
8/27/20241.25 undefined
8/26/20241.36 undefined

Nektar Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Nektar Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nektar Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nektar Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nektar Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nektar Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nektar Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nektar Therapeutics’s growth potential.

Nektar Therapeutics Revenue, EBIT and net profit per share

DateNektar Therapeutics RevenueNektar Therapeutics EBITNektar Therapeutics Net Income
2030e192.68 M undefined19.89 M undefined0 undefined
2029e61.71 M undefined-43.04 M undefined0 undefined
2028e197.55 M undefined-46.97 M undefined0 undefined
2027e113.83 M undefined-154.69 M undefined0 undefined
2026e67.17 M undefined-179.72 M undefined-115.66 M undefined
2025e66.11 M undefined-171.25 M undefined-127.11 M undefined
2024e78.9 M undefined-157.63 M undefined-156.14 M undefined
202390.12 M undefined-135.23 M undefined-276.06 M undefined
202292.1 M undefined-240.3 M undefined-368.2 M undefined
2021101.9 M undefined-446.1 M undefined-523.8 M undefined
2020152.9 M undefined-379.9 M undefined-444.4 M undefined
2019114.6 M undefined-440 M undefined-440.7 M undefined
20181.19 B undefined687.9 M undefined681.3 M undefined
2017307.7 M undefined-43.6 M undefined-96.7 M undefined
2016165.4 M undefined-112.9 M undefined-153.5 M undefined
2015230.8 M undefined-29.4 M undefined-81.2 M undefined
2014200.7 M undefined-16.5 M undefined-53.9 M undefined
2013148.9 M undefined-120.1 M undefined-162 M undefined
201281.2 M undefined-139.5 M undefined-171.9 M undefined
201171.5 M undefined-123.9 M undefined-134 M undefined
2010159 M undefined-15.7 M undefined-37.9 M undefined
200971.9 M undefined-95.1 M undefined-102.5 M undefined
200890.2 M undefined-150.8 M undefined-34.3 M undefined
2007273 M undefined-86.9 M undefined-32.8 M undefined
2006217.7 M undefined-132.1 M undefined-154.8 M undefined
2005126.3 M undefined-109.4 M undefined-185.1 M undefined
2004114.3 M undefined-73.9 M undefined-101.9 M undefined

Nektar Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
000000.010.020.020.040.050.080.090.110.110.130.220.270.090.070.160.070.080.150.20.230.170.311.190.110.150.10.090.090.080.070.070.110.20.060.19
----200.00100.00166.6731.2595.2424.3950.9822.0812.777.5510.5372.2225.81-67.03-21.11123.94-55.3514.0882.7235.1415.00-28.2686.06288.60-90.4433.33-33.55-8.91-2.17-13.33-15.381.5268.6674.34-69.04214.75
--------100.00100.0094.8192.5585.8582.4671.4345.6245.7961.1157.7583.6569.0161.7374.3286.0085.2281.8290.2397.9081.5887.5076.2476.0962.22-------
000000000.040.050.070.090.090.090.090.10.130.060.040.130.050.050.110.170.20.140.281.170.090.130.080.070.060000000
0-1-2-5-8-11-13-22-30-63-110-98-64-73-109-132-86-150-95-15-123-139-120-16-29-112-43687-440-379-446-240-135-157-171-179-154-46-4319
----500.00-266.67-183.33-81.25-104.76-73.17-123.53-142.86-104.26-60.38-64.04-86.51-60.83-31.50-166.67-133.80-9.43-173.24-171.60-81.08-8.00-12.61-67.88-14.0157.59-385.96-249.34-441.58-260.87-150.00-201.28-259.09-267.16-136.28-23.35-70.499.90
0-1-2-5-7-9-10-18-38-97-250-107-65-101-185-154-32-34-102-37-134-171-162-53-81-153-96681-440-444-523-368-276-156-127-1150000
--100.00150.0040.0028.5711.1180.00111.11155.26157.73-57.20-39.2555.3883.17-16.76-79.226.25200.00-63.73262.1627.61-5.26-67.2852.8388.89-37.25-809.38-164.610.9117.79-29.64-25.00-43.48-18.59-9.45----
12.812.812.812.219.722.427.631.4344253.155.355.878.585.989.891.992.492.894.1112.9114.8115.7126.9132.5139.6156180.1175178.6183.3187.11900000000
----------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Nektar Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Nektar Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
19921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                               
00.010.010.020.040.10.080.140.480.340.290.290.240.480.460.480.380.40.320.240.280.240.240.310.390.31.341.321.060.730.510.3
00000011.80.64.54.46.212.812.547.121.611.24.825.14.95.82.23.619.915.7543.236.838.922.561.21
00000000000000000000000000000000
0000000003.26.38.610.718.614.712.29.36.57.312.718.313.51311.311.110.711.412.715.315.819.216.1
00.10.40.51.20.80.77.47.68.86.35.812.312.514.67.16.76.25.717.913.45.233.89.810.114.947.847.221.923.315.89.78
00.010.010.020.040.10.080.150.490.360.310.310.280.520.540.520.410.410.350.280.310.260.290.350.430.331.441.421.140.80.550.33
0.51.42.32.73.818.749.963.9110.5142.4143.5149.4151.2142.1133.8114.473.678.389.878.672.26770.471.365.647.548.9199.2186.1177.585.936.86
00000006.39.10.7012.417590.28.30000173.80000057.1582.9279.1136.764.8025.83
00000000000000000000000000000000
00000003.13.122.215.5116.513.53.62.70000000000000000
000000021.9131.6130.1130.1130.178.478.478.476.576.576.576.576.576.576.576.576.576.576.576.576.576.576.50
0.10.10.20.20.20.10.14.211.99.56.67.42.614.58.96.34.27.11134.433.26.60.80.814.211.52.72.24.64
0.61.52.52.9418.85079.5136.5306.4295.7310.3465.4338.7233201.8154.3161.9167.3329.9183.1176.7153.5148.6142.9182.1712.5555.8400.8321.5164.667.33
00.010.020.020.040.120.130.230.630.670.610.620.740.860.770.730.560.580.520.610.50.430.440.50.570.512.151.981.541.120.710.4
                                                               
5.710.725.938.262.80000040000000000000000000000.02
000000.140.170.180.470.710.710.781.191.231.281.31.311.331.351.61.621.641.821.882.112.213.153.273.393.523.573.61
-2-4.8-10.1-17.8-27.7-37.7-56-94.5-191.9-441.9-549.3-615.2-717.1-902.2-1,057-1,089.8-1,124.1-1,226.6-1,264.5-1,398.5-1,570.4-1,732.4-1,786.3-1,867.5-2,021-2,117.9-1,424.1-1,864.7-2,309.2-2,833-3,201.2-3,477.25
00-0.4-0.3-0.1-0.5-1-0.14.20.11.40.9-3.1-4.70.11.61.411-1.1-0.4-1.2-1.6-2.2-2.4-2.1-6.3-1-2.3-4.2-6.90.08
00000000000000000000000000000000
00.010.020.020.030.10.120.090.280.270.210.160.470.330.230.210.190.10.090.20.05-0.090.040.010.090.091.721.411.080.680.370.13
00.20.30.71.163.713.46.57.78.78.17.116.17.23.613.83.17.232.99.12.72.42.84.85.919.222.19.7139.85
0.30.20.71.22.24.44.76.817.833.63218.717.126.634.870.239.128.629.931.441.444.326.822.635.13261.879.593.575.555.241.42
00.10.10.62.76.74.44.84.917.12218.729.926.320.32215.4121.42726.134.344.83031.634.319.414.46.40.1000
00000000000000102.70000215000000000000
0.10.20.20.20.20.10.1010.811.31.50.50.72.30000004.54.8000248.70000
0.40.71.32.76.217.212.92530.259.263.746.855.669.5165.798.168.3153.164.1275.578.698.26461.472.256.282.1353.8115.785.268.251.27
0.20.70.50.40.25.14.9113.3314.4331.1331391.7197.5438.1334.8336.6235.3233.823214.6136.6203129.1242.8243.5245.224700000
00000000000000000000000000000000
000000.50.91.876.75.214.124.42440.875.966.786.4134.5118.6235.6223.2212.1188.2165.1119.7103.6218.1345.7352.5275.8215.78
0.20.70.50.40.25.65.8115.1321.4337.8336.2405.8221.9462.1375.6412.5302320.2366.5133.2372.2426.2341.2431408.6364.9350.6218.1345.7352.5275.8215.78
0.61.41.83.16.422.818.7140.1351.6397399.9452.6277.5531.6541.3510.6370.3473.3430.6408.7450.8524.4405.2492.4480.8421.1432.7571.9461.4437.7344267.05
00.010.020.020.040.120.130.230.630.670.610.620.740.860.770.720.560.580.520.610.50.430.440.50.570.512.151.981.541.120.710.4
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Nektar Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Nektar Therapeutics's financial health and stability.

Assets

Nektar Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Nektar Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Nektar Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Nektar Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0-1-2-5-7-9-10-18-38-97-250-107-65-101-185-154-32-34-102-37-134-171-162-53-81-153-96681-440-444-523-368-276
0000112369381716182533292214161514141212151410131414137
000000000000000000000000000000020
00001211-45389-20-64-8106-26117-64-15120-116-347-37-392116-230-19
0000000011481535-612773743-972047394210632493975153176194214105128
0000000008151719251517171411-1010-9171720202019199000
000000000000000000001-111000000002
0-1-2-4-5-55-19-15-35-50-75-76-78-78-92146-14539-55-113-129-38-142-73-117-80718-328-313-412-304-192
000-1-1-2-17-34-35-56-34-16-18-27-18-22-32-18-20-31-9-10-4-10-11-6-9-14-26-7-15-50
00-4-1-13-3-85-6-82-299-7736-5-14132-116-32274-14916-11211349-37-14-82-28-1,379206496202365139
00-30-12-1-6828-46-243-425213-11450-940293-12848-10212354-27-3-76-19-1,365233503217371140
000000000000000000000000000000000
0000004010446116-198-3232-10-105-50-1-1-2-174-3-3236-5-500-250000
055141224713611764022114222304822448163322095985223233300
0551412247636106438223810120727411-101-49372222621531302035485223-803610
000000000-4000000000000197-3-7-1370000146300
000000000000000000000000000000000
03-28-614-4108102-105019-12229-1971279-106-31-21013-26434-54190-98102-17363-52
-0.3-1.6-3.4-5.4-6.6-8-12.3-53.8-51.1-91.8-85.1-91.3-94.9-105.3-96-115.2113.5-164.719-87.4-123.4-140.4-42.6-152-84.3-123.4-90.1704-355-320.6-427.7-309.7-193.47
000000000000000000000000000000000

Nektar Therapeutics stock margins

The Nektar Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nektar Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nektar Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nektar Therapeutics's sales revenue. A higher gross margin percentage indicates that the Nektar Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nektar Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nektar Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nektar Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nektar Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nektar Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nektar Therapeutics Margin History

Nektar Therapeutics Gross marginNektar Therapeutics Profit marginNektar Therapeutics EBIT marginNektar Therapeutics Profit margin
2030e62.53 %10.32 %0 %
2029e62.53 %-69.75 %0 %
2028e62.53 %-23.77 %0 %
2027e62.53 %-135.89 %0 %
2026e62.53 %-267.55 %-172.19 %
2025e62.53 %-259.04 %-192.28 %
2024e62.53 %-199.78 %-197.9 %
202362.53 %-150.05 %-306.31 %
202276.44 %-260.91 %-399.78 %
202175.56 %-437.78 %-514.03 %
202087.25 %-248.46 %-290.65 %
201981.33 %-383.94 %-384.55 %
201897.96 %57.65 %57.09 %
201790.09 %-14.17 %-31.43 %
201681.74 %-68.26 %-92.81 %
201585.23 %-12.74 %-35.18 %
201485.8 %-8.22 %-26.86 %
201374.14 %-80.66 %-108.8 %
201262.56 %-171.8 %-211.7 %
201169.37 %-173.29 %-187.41 %
201083.9 %-9.87 %-23.84 %
200957.02 %-132.27 %-142.56 %
200861.09 %-167.18 %-38.03 %
200745.97 %-31.83 %-12.01 %
200645.75 %-60.68 %-71.11 %
200571.5 %-86.62 %-146.56 %
200482.68 %-64.65 %-89.15 %

Nektar Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Nektar Therapeutics earnings per share therefore indicates how much revenue Nektar Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nektar Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nektar Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nektar Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nektar Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Nektar Therapeutics Revenue, EBIT and net profit per share

DateNektar Therapeutics Sales per ShareNektar Therapeutics EBIT per shareNektar Therapeutics Earnings per Share
2030e1.05 undefined0 undefined0 undefined
2029e0.34 undefined0 undefined0 undefined
2028e1.07 undefined0 undefined0 undefined
2027e0.62 undefined0 undefined0 undefined
2026e0.36 undefined0 undefined-0.63 undefined
2025e0.36 undefined0 undefined-0.69 undefined
2024e0.43 undefined0 undefined-0.85 undefined
20230.47 undefined-0.71 undefined-1.45 undefined
20220.49 undefined-1.28 undefined-1.97 undefined
20210.56 undefined-2.43 undefined-2.86 undefined
20200.86 undefined-2.13 undefined-2.49 undefined
20190.65 undefined-2.51 undefined-2.52 undefined
20186.63 undefined3.82 undefined3.78 undefined
20171.97 undefined-0.28 undefined-0.62 undefined
20161.18 undefined-0.81 undefined-1.1 undefined
20151.74 undefined-0.22 undefined-0.61 undefined
20141.58 undefined-0.13 undefined-0.42 undefined
20131.29 undefined-1.04 undefined-1.4 undefined
20120.71 undefined-1.22 undefined-1.5 undefined
20110.63 undefined-1.1 undefined-1.19 undefined
20101.69 undefined-0.17 undefined-0.4 undefined
20090.77 undefined-1.02 undefined-1.1 undefined
20080.98 undefined-1.63 undefined-0.37 undefined
20072.97 undefined-0.95 undefined-0.36 undefined
20062.42 undefined-1.47 undefined-1.72 undefined
20051.47 undefined-1.27 undefined-2.15 undefined
20041.46 undefined-0.94 undefined-1.3 undefined

Nektar Therapeutics business model

"Answer: Nektar Therapeutics is an American biopharmaceutical company based in San Francisco, specializing in the discovery and development of drugs for the treatment of cancer, autoimmune, and chronic metabolic diseases. The company was founded in 1990 by CEO Howard Robin and his team, initially focused on researching new technologies for drug development and later shifted to developing drugs for cancer therapy. Nektar Therapeutics has a unique business model that involves partnering with major pharmaceutical companies and other partners to develop a wide range of products, which are then licensed to these partners for commercialization and distribution. The company operates in several sectors, including oncology, pain management, autoimmune diseases, and metabolic diseases. Its important products include Movantik for opioid-induced constipation and ONZEALD for pancreatic cancer treatment. Nektar Therapeutics has made significant progress in developing immunoncology drugs, with potential projects such as NKTR-214 for advanced skin cancers. With its leading position in innovative drug development and strategic partnerships, the company has the potential to become a major player in cancer therapy." Nektar Therapeutics is one of the most popular companies on Eulerpool.com.

Nektar Therapeutics Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Nektar Therapeutics Revenue by Segment

Segmente20222021202020192018
Non-cash royalty revenue related to the sales of future royalties69.79 M USD77.75 M USD---
Product sales20.35 M USD23.73 M USD---
License, collaboration and other revenue1.91 M USD436,000 USD---
Royalty revenue-----
License collaboration and other revenue----1.1 B USD
Cash And NonCash Royalties69.8 M USD77.7 M USD---
Non-cash royalty revenue related to sale of future royalties--48.56 M USD36.3 M USD33.31 M USD
License, collaboration and other revenue--55.85 M USD16.98 M USD-
Royalty revenue--31 M USD41.22 M USD-
Royalty Revenue----41.98 M USD
Product sales--17.5 M USD20.12 M USD-
Product Sales----20.77 M USD

Nektar Therapeutics Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Nektar Therapeutics Revenue by Segment

DateEuropeanUnited States
2018102.53 M USD1.09 B USD
2017116.9 M USD190.81 M USD
2016126.29 M USD39.15 M USD

Nektar Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Nektar Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Nektar Therapeutics shares outstanding

The number of shares was Nektar Therapeutics in 2023 — This indicates how many shares 190.001 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nektar Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nektar Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nektar Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nektar Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Nektar Therapeutics.

Nektar Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.21 -0.25  (-20.37 %)2024 Q2
3/31/2024-0.19 -0.19  (1.96 %)2024 Q1
12/31/2023-0.22 -0.22  (-1.57 %)2023 Q4
9/30/2023-0.2 -0.24  (-17.99 %)2023 Q3
6/30/2023-0.29 -0.27  (6.77 %)2023 Q2
3/31/2023-0.26 -0.32  (-24.22 %)2023 Q1
12/31/2022-0.46 -0.32  (30.65 %)2022 Q4
9/30/2022-0.46 -0.31  (32.39 %)2022 Q3
6/30/2022-0.95 -0.85  (10.99 %)2022 Q2
3/31/2022-0.69 -0.49  (29.07 %)2022 Q1
1
2
3
4
5
...
11

Eulerpool ESG Scorecard© for the Nektar Therapeutics stock

Eulerpool World ESG Rating (EESG©)

81/ 100

🌱 Environment

87

👫 Social

99

🏛️ Governance

56

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Nektar Therapeutics list of shareholders

%
Name
Stocks
Change
Date
9.99565 % Deep Track Capital LP18,400,000012/31/2023
6.54220 % The Vanguard Group, Inc.12,042,873-18,27412/31/2023
4.24750 % Acadian Asset Management LLC7,818,804192,41612/31/2023
3.80364 % PRIMECAP Management Company7,001,747-196,23612/31/2023
3.24500 % Monaco asset management S.A.M.5,973,3871,163,78612/31/2023
3.05574 % Citadel Advisors LLC5,625,000012/31/2023
2.89302 % Renaissance Technologies LLC5,325,4751,818,79412/31/2023
2.86183 % Two Sigma Investments, LP5,268,058-1,276,43312/31/2023
2.85517 % GSA Capital Partners LLP5,255,7903,414,71212/31/2023
2.25340 % BlackRock Institutional Trust Company, N.A.4,148,055-1,374,05112/31/2023
1
2
3
4
5
...
10

Nektar Therapeutics Executives and Management Board

Mr. Howard Robin70
Nektar Therapeutics President, Chief Executive Officer, Director (since 2007)
Compensation 11.28 M
Mr. Mark Wilson51
Nektar Therapeutics Senior Vice President, Chief Legal Officer
Compensation 4.57 M
Dr. Jonathan Zalevsky48
Nektar Therapeutics Chief Research and Development Officer
Compensation 4.35 M
Mr. Robert Chess66
Nektar Therapeutics Independent Chairman of the Board (since 1991)
Compensation 213,743
Mr. Roy Whitfield69
Nektar Therapeutics Lead Independent Director
Compensation 208,993
1
2
3

Nektar Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Bausch Health Stock
Bausch Health
SupplierCustomer0,800,840,520,750,840,24
Roche Holding Stock
Roche Holding
SupplierCustomer0,760,79-0,450,04-0,36-0,66
Johnson & Johnson Stock
Johnson & Johnson
SupplierCustomer0,55--0,68-0,72-0,54-0,62
Pfizer Stock
Pfizer
SupplierCustomer0,470,71-0,170,49-0,55-0,79
UCB Stock
UCB
SupplierCustomer0,440,68-0,09-0,45-0,39-0,37
Certara Stock
Certara
SupplierCustomer0,230,370,300,890,74-
Nykode Therapeutics Stock
Nykode Therapeutics
SupplierCustomer0,170,620,420,870,820,39
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer-0,18-0,39-0,75-0,90-0,70-0,69
Gilead Sciences Stock
Gilead Sciences
SupplierCustomer-0,190,18-0,020,810,760,35
AstraZeneca Stock
AstraZeneca
SupplierCustomer-0,350,44-0,73-0,90-0,78-0,75
1
2

Most common questions regarding Nektar Therapeutics

What values and corporate philosophy does Nektar Therapeutics represent?

Nektar Therapeutics is a leading biopharmaceutical company that values innovation, collaboration, and patient-centered focus. Their corporate philosophy revolves around developing medicines that make a meaningful impact on patients' lives. Nektar Therapeutics strives to address unmet medical needs by leveraging cutting-edge science and technologies. With a commitment to improving health outcomes, the company collaborates with various stakeholders including scientists, physicians, and caregivers to develop breakthrough therapies. Nektar Therapeutics prioritizes patient safety, ethical behavior, and transparency in all of its operations. By fostering a culture of excellence and accountability, Nektar Therapeutics remains dedicated to improving the future of healthcare through its pioneering efforts.

In which countries and regions is Nektar Therapeutics primarily present?

Nektar Therapeutics is primarily present in the United States.

What significant milestones has the company Nektar Therapeutics achieved?

Some significant milestones achieved by Nektar Therapeutics include the successful development and commercialization of several pharmaceutical products. Notably, the company received approval for its breakthrough pain medication, NKTR-181, by the U.S. Food and Drug Administration (FDA) in 2020. Nektar also achieved positive results in clinical trials for its immunotherapy drug, NKTR-214, which showed promising efficacy in treating various types of cancer. Additionally, the company has established collaborations with several pharmaceutical giants, such as Bristol Myers Squibb and Eli Lilly, further enhancing its position in the industry. Nektar Therapeutics continues to innovate and advance its pipeline of therapeutic candidates to address unmet medical needs.

What is the history and background of the company Nektar Therapeutics?

Nektar Therapeutics is a biopharmaceutical company that specializes in developing innovative therapies. Founded in 1990, Nektar has a strong history of breakthrough advancements in drug delivery and discovery. The company's mission is to improve the lives of patients by creating novel treatments for various diseases, including cancer, autoimmune disorders, and chronic pain. With its cutting-edge research and development programs, Nektar Therapeutics has established itself as a prominent player in the pharmaceutical industry. Over the years, Nektar has collaborated with leading organizations and received recognition for its contributions to healthcare. The company's relentless pursuit of scientific excellence is reflected in its commitment to delivering transformative medicines to patients worldwide.

Who are the main competitors of Nektar Therapeutics in the market?

The main competitors of Nektar Therapeutics in the market include pharmaceutical companies such as Pfizer, Bristol-Myers Squibb, Merck & Co., and Eli Lilly and Company. These companies compete with Nektar Therapeutics in various therapeutic areas, including oncology and immunology.

In which industries is Nektar Therapeutics primarily active?

Nektar Therapeutics primarily operates in the biotechnology and pharmaceutical industries.

What is the business model of Nektar Therapeutics?

The business model of Nektar Therapeutics revolves around the development and commercialization of innovative therapies aimed at addressing unmet medical needs. Nektar Therapeutics focuses on creating novel drug candidates using its proprietary technology platforms, including advanced polymer conjugate technology and its Immuno-Oncology platform. The company collaborates with pharmaceutical and biotechnology partners to bring these therapeutic solutions to market. Nektar Therapeutics strives to leverage its expertise in drug discovery and development to deliver effective and differentiated treatments across various therapeutic areas, including oncology, immunology, and pain management.

What is the P/E ratio of Nektar Therapeutics 2024?

The Nektar Therapeutics P/E ratio is -1.58.

What is the P/S ratio of Nektar Therapeutics 2024?

The Nektar Therapeutics P/S ratio is 3.13.

What is the AlleAktien quality score of Nektar Therapeutics?

The AlleAktien quality score for Nektar Therapeutics is 1/10.

What is the revenue of Nektar Therapeutics 2024?

The expected Nektar Therapeutics revenue is 78.9 M USD.

How high is the profit of Nektar Therapeutics 2024?

The expected Nektar Therapeutics profit is -156.14 M USD.

What is the business model of Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company specializing in the research, development, and commercialization of new therapies for cancer, autoimmune diseases, and chronic pain. The company is divided into four areas: oncology, immunology, pain therapy, and pulmonology.

What is the Nektar Therapeutics dividend?

Nektar Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Nektar Therapeutics pay dividends?

The dividend cannot currently be calculated for Nektar Therapeutics or the company does not pay out a dividend.

What is the Nektar Therapeutics ISIN?

The ISIN of Nektar Therapeutics is US6402681083.

What is the Nektar Therapeutics WKN?

The WKN of Nektar Therapeutics is 165417.

What is the Nektar Therapeutics ticker?

The ticker of Nektar Therapeutics is NKTR.

How much dividend does Nektar Therapeutics pay?

Over the past 12 months, Nektar Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nektar Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Nektar Therapeutics?

The current dividend yield of Nektar Therapeutics is .

When does Nektar Therapeutics pay dividends?

Nektar Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nektar Therapeutics?

Nektar Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Nektar Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nektar Therapeutics located?

Nektar Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nektar Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nektar Therapeutics from 9/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/22/2024.

When did Nektar Therapeutics pay the last dividend?

The last dividend was paid out on 9/22/2024.

What was the dividend of Nektar Therapeutics in the year 2023?

In the year 2023, Nektar Therapeutics distributed 0 USD as dividends.

In which currency does Nektar Therapeutics pay out the dividend?

The dividends of Nektar Therapeutics are distributed in USD.

All fundamentals about Nektar Therapeutics

Our stock analysis for Nektar Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nektar Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.